-
Analysis of transaction trends of Chinese biopharmaceutical companies in 2021
Time of Update: 2022-04-22
In this report, the scope of data analyzed is mainly the transactions related to Chinese domestic enterprises in 2021 provided in the NextPharma transaction module of Pharma Cube ;The trend analysis is mainly based on project transactions, unless otherwise specified, does not include company mergers and acquisitions information .
-
Phase 2/3 clinical trials of Moderna's COVID-19 vaccine for children under 6 years old meet primary endpoint
Time of Update: 2022-04-22
The study was conducted in children 6 months to 2 years old and 2 years old to under 6 years old, and the interim analysis showed that the 25µg two-dose immunization schedule showed strong neutralizing antibody responses and good safety in both age groups.
-
A number of longevity drug concept stocks are booming. Does mastering NMN mean having a wealth code?
Time of Update: 2022-04-22
Recently, NMPA of the State Food and Drug Administration announced the information that NMN (β-nicotinamide mononucleotide) substances can be registered as new raw materials for "cosmetics", which is considered to be a positive signal for the industry .
-
In order to create the next growth curve, pharmaceutical machine companies are deploying in many fields
Time of Update: 2022-04-22
At present, in order to create the next growth curve and usher in more development opportunities, many pharmaceutical equipment companies have begun to take action and expand their layout in many pharmaceutical fields .
-
Henlius PD-1 Monoclonal Antibody Slulimumab Injection Approved for Marketing
Time of Update: 2022-04-22
In April 2021, slulimumab submitted its first indication marketing application in China, targeting unresectable or metastatic highly microsatellite unstable solid tumors that have failed standard therapy .
-
Two drugs to be included in breakthrough therapy varieties involve Fosun Kite, Mingju Bio
Time of Update: 2022-04-22
On March 24, the CDE official website recently revealed that Fosun Kite FKC889 and Mingju Bio’s JWCAR029 are planned to be included in breakthrough therapy varieties . It is reported that the propose
-
Takeda's ALK inhibitor approved in China
Time of Update: 2022-04-22
On March 24, the official website of the State Drug Administration announced that the new drug application for the ALK inhibitor brigatinib submitted by Takeda has been approved .
In April 2017, it received accelerated approval from the FDA for the second-line treatment of patients with ALK-positive metastatic NSCLC .
-
Consistency evaluation of this pharmaceutical company has been harvested again and again, and 2 varieties have been evaluated within a month
Time of Update: 2022-04-22
Tianyao announced on the evening of March 22 that its subsidiary Jinyao Pharmaceutical's Dexamethasone Sodium Phosphate Injection passed the quality and efficacy consistency evaluation of generic drugs .
-
Gene therapy continues to receive a lot of investment, and a domestic pharmaceutical equipment company is accelerating its deployment
Time of Update: 2022-04-21
Analysts pointed out that the global gene therapy industry has been developing rapidly in recent years, and financing has been heating up day by day, including venture capital, private equity investment, and IPO.
-
Novo Nordisk's GLP-1 agonist Ozempic 2mg dose approved by US FDA
Time of Update: 2022-04-21
In addition, Ozempic is effective in reducing the risk of major cardiovascular events (MACE) in patients with type 2 diabetes and cardiovascular disease .
In addition, patients in the trial had an average baseline weight of 219 pounds, and at week 40 of treatment, the Ozempic 2 mg group lost 14.
-
CXO enters the performance release period, and a large number of companies have outstanding performance
Time of Update: 2022-04-21
As of March 28, among the more than ten CXO companies listed in China, 6 companies including WuXi AppTec, WuXi Biologics, Pharmaron, Zhaoyan New Drug, Medicilon, and Proton have released their 2021 annual reports.
-
The 30 billion Chinese patent medicine market for the respiratory system will be approved by Youersheng Pharmaceutical's Tianxing Kechuan Patch
Time of Update: 2022-04-21
Sales of Chinese patent medicines for respiratory diseases in public medical institutions in China (unit: 10,000 yuan) Source: Minet.
hospital hospital hospital Sales of Chinese patent medicines for respiratory diseases in public medical institutions in China (unit: 10,000 yuan) Source: Minet.
-
ALS new drug research and development both suffered setbacks: Biogen/Ionis terminated the phase I trial of Amylyx's drug listing, which was questioned by FDA
Time of Update: 2022-04-21
On March 28, Biogen and its partner Ionis Pharmaceuticals released the first-line results of the Phase I clinical trial of BIIB078 .
The FDA questioned the company's ALS treatment AMX0035 on March 28, arguing that data on the drug's effectiveness were inconclusive .
-
Recently, a number of pharmaceutical companies have obtained CEP certificates for their APIs
Time of Update: 2022-04-21
It is worth mentioning that, in order to expand the market share of foreign sales, a large number of enterprises are currently accelerating the submission of product access applications to relevant agencies in many countries, and many APIs have recently obtained CEP certificates .
-
Junshi Bio's KRAS inhibitor approved for clinical use
Time of Update: 2022-04-21
On March 28, the CDE official website showed that Junshi Bio's KRAS inhibitor JS116 applied for clinical application in China for the first time .
Only domestic companies have entered the clinical KRAS project.
-
The fifty-seventh batch of reference preparations for chemical generic drugs (draft for comments) was released
Time of Update: 2022-04-21
25, 2019) issued by the National Bureau on March 28, 2019, the center organized the selection of The fifty-seventh batch of reference preparations is now publicized for comments .
docx 2 Chemical Generic Drug Reference Preparation Objection Application Form.
-
The heavy-holding stocks of the pharmaceutical fund are exposed!
Time of Update: 2022-04-21
The new periodic report of Southern Pharmaceutical Innovation Stock A shows that CXO stocks account for half of the top ten heavyweight stocks, including Yaoshi Technology, Tigermed, WuXi AppTec, Asymchem, GenScript Biotechnology, and Zhaoyan New Drug .
-
Hengrui's another blockbuster contrast agent product was approved, and it successfully won the first visit + the first review!
Time of Update: 2022-04-21
+The first company to pass the review, and it also broke the market monopoly of the original researcher Bayer in China for many years, which will help to consolidate the company's position as the head company of contrast agents .
-
Two innovative drugs from Hansoh Pharma launched clinical trials on the same day
Time of Update: 2022-04-21
On March 28, the Insight database showed that the two innovative drugs HS-10370 and HS-10382 of Hansoh Pharma registered and started clinical trials on the same day .
Clinical application of innovative drug projects of Hansoh Pharma in the past 5 years*Only the first declaration is countedFrom: Insight database (http://db.
-
In order to accelerate innovation, domestic and foreign pharmaceutical companies have set off a new round of cooperation
Time of Update: 2022-04-21
Roche has announced a partnership with Bristol-Myers Squibb (BMS) to leverage two innovative digital pathology algorithms to support advancements in pathology detection in clinical trials .
In addition, Aide Bio and the French pharmaceutical company Pierre Fabre (Pierre Fabre Group) also reached a strategic cooperation in companion diagnostics in February .
